Aleafia Health Subsidiary Emblem Germany Submits EU-GMP Certification Application

• Successful application would allow for cannabis production and export to EU market
  
• Emblem Germany cannabis distribution center to be completed later this month
• Experienced senior management team has led the buildout and operation of multiple EU-GMP certified facilities
• Cannabis production operations underway at Paris Facility expansion, three business days following granting of new licence

TORONTO, May 07, 2020 (GLOBE NEWSWIRE) -- Aleafia Health Inc.’s (TSX: ALEF, OTC: ALEAF) (“Aleafia Health” or the “Company”) indirect subsidiary, Emblem Germany GmbH (“Emblem Germany”), has formally submitted its application to German regulators for EU Good Manufacturing Practices (“EU-GMP”) certification.

The Company’s newly licensed Paris Facility has been purpose built to meet EU-GMP certification requirements, pharmaceutical-grade production’s highest standard, and as a result, provides wide access to global markets. The application, if successful, would allow the Company’s Paris Facility to produce and export EU-GMP certified cannabis products to the European Union.

Cannabis production operations commenced on May 6, 2020 at the Paris Facility Phase II expansion, only three business days following receipt of the amended Health Canada licence.

Aleafia Health indirectly owns 60 percent of Emblem Germany, by way of a joint-venture between Emblem and German pharmaceutical wholesaler and logistics company, Acnos Pharma GmbH (“Acnos”). It is difficult to ascertain the timeline for securing certification, but the Company intends to continue preparing for an eventual facility inspection.

Aleafia Health and Acnos’ senior management are directing the effort and have previously led the build-out, certification and operation of multiple EU-GMP certified pharmaceutical production facilities in The Netherlands, Germany and North America.

Later this month, Acnos is expected to complete a new state-of-the-art pharmaceutical production and supply chain facility in Aachen Brand, Germany. It contains a dedicated cannabis distribution hub that Acnos owns and Emblem Germany will operate, allowing the Company to commence sales upon receipt of necessary German export and import permits.

“The state-of-art expansion of the Paris Facility, purpose built to meet EU-GMP standards, creates a unique competitive advantage with significant barriers to entry,” said Aleafia Health CEO Geoffrey Benic. “We look forward to leveraging the skillsets of our strong partner Acnos Pharma along with our management team’s in-house EU-GMP expertise.”